<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04549584</url>
  </required_header>
  <id_info>
    <org_study_id>2004-261-112</org_study_id>
    <nct_id>NCT04549584</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer</brief_title>
  <acronym>NEO-SMART</acronym>
  <official_title>Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      prospective study for response of neoadjuvant chemotherapy in metaplastic carcinoma of triple&#xD;
      negative breast cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vimentin/Pan CK staining will be performed on tissues of patient who visited Seoul National&#xD;
      University Hospital and were diagnosed with triple negative breast cancer and decided to&#xD;
      perform neoadjuvant chemotherapy under clinical judgement.&#xD;
&#xD;
      Histologically determined to be a metaplastic breast cancer or tested positive for&#xD;
      vimentin/Pan CK patients decides as the metaplastic breast cancer. They evaluate the response&#xD;
      rate of the neoadjuvant chemotherapy.&#xD;
&#xD;
      Patients with vimentin/Pan CK negative are diagnosed with non-metaplastic breast cancer and&#xD;
      this group also confirms the response rate of neoadjuvant chemotherapy.&#xD;
&#xD;
      The group of metaplastic breast cancer will enroll 50 people, and the group of&#xD;
      non-metaplastic breast cancer will enroll 100 people.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    due to poor enrolled patients&#xD;
  </why_stopped>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Actual">December 16, 2020</completion_date>
  <primary_completion_date type="Actual">December 16, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>response rate of neoadjuvant chemotherapy</measure>
    <time_frame>After neoadjuvant chemotherapy was finished. Average 6 month later.</time_frame>
    <description>response criteria for neoadjuvant chemotherapy-complete response (CR), partial response (PR), and no response (NR)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">3</enrollment>
  <condition>Metaplastic Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>metaplastic breast cancer</arm_group_label>
    <description>Histologically determined to be a metaplastic breast cancer or tested positive for vimentin/Pan CK patients decides as the metaplastic breast cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-metaplastic breast cancer</arm_group_label>
    <description>Patients with vimentin/Pan CK negative are diagnosed with non-metaplastic breast cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Vimentin/pan CK stain</intervention_name>
    <description>Vimentin/pan CK stain positive/negative</description>
    <arm_group_label>metaplastic breast cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tissue obtained by core needle biopsy&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  over 20 years old&#xD;
&#xD;
          -  patients with triple negative breast cancer diagnosed Seoul National University&#xD;
             Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  over 20 years old&#xD;
&#xD;
          -  patients with triple negative breast cancer diagnosed Seoul National University&#xD;
             Hospital&#xD;
&#xD;
          -  patients who decided to perform neoadjuvant chemotherapy under clinical judgement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  not applicable&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Hyeong Gon Moon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011 Sep;68(18):3033-46. doi: 10.1007/s00018-011-0735-1. Epub 2011 Jun 3. Review.</citation>
    <PMID>21637948</PMID>
  </reference>
  <reference>
    <citation>Schwartz TL, Mogal H, Papageorgiou C, Veerapong J, Hsueh EC. Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies. Exp Hematol Oncol. 2013 Nov 14;2(1):31. doi: 10.1186/2162-3619-2-31.</citation>
    <PMID>24499560</PMID>
  </reference>
  <reference>
    <citation>Adams S. Dramatic response of metaplastic breast cancer to chemo-immunotherapy. NPJ Breast Cancer. 2017 Mar 29;3:8. doi: 10.1038/s41523-017-0011-0. eCollection 2017.</citation>
    <PMID>28649648</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 30, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hyeong-Gon Moon</investigator_full_name>
    <investigator_title>Medical doctor, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

